Evidence map›Paper›PMID 39217445›Full record

Trial reportEuropean heart journal. Cardiovascular pharmacotherapy2025

Effects of beta-blockers on quality of life and well-being in patients with myocardial infarction and preserved left ventricular function-a prespecified substudy from REDUCE-AMI.

Katarina Mars, Sophia Humphries, Philip Leissner, Martin Jonsson, Patric Karlström, Jörg Lauermann, Joakim Alfredsson, Thomas Kellerth, Annica Ravn-Fischer, David Erlinge and 6 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European heart journal. Cardiovascular pharmacotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Katarina MarsDepartment of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm, Sjukhusbacken 10, 188 83, Sweden.ORCID 0000-0002-6739-1558
Sophia HumphriesDepartment of Women's and Children's Health, Uppsala University, Uppsala 751 85, Sweden.ORCID 0000-0002-3680-6351
Philip LeissnerDepartment of Women's and Children's Health, Uppsala University, Uppsala 751 85, Sweden.
Martin JonssonDepartment of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm, Sjukhusbacken 10, 188 83, Sweden.ORCID 0000-0002-3539-8317
Patric KarlströmDepartment of Internal Medicine, Ryhov County Hospital, Jönköping 551 85  Sweden.
Jörg LauermannDepartment of Internal Medicine, Ryhov County Hospital, Jönköping 551 85  Sweden.
Joakim AlfredssonDepartment of Cardiology and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping 581 83, Sweden.ORCID 0000-0002-1415-7178
Thomas KellerthDivision of Cardiology and Emergency medicine, Centralsjukhuset Karlstad, Karlstad 651 82, Sweden.
Annica Ravn-FischerDepartment of Cardiology, Sahlgrenska University Hospital, Gothenburg 405 30, Sweden.ORCID 0000-0003-2585-1592
David ErlingeDepartment of Cardiology, Clinical Sciences, Lund University, Skane University Hospital, Lund 222 42, Sweden.
Bertil LindahlDepartment of Medical Sciences, Cardiology, Uppsala University, Uppsala 751 85, Sweden.ORCID 0000-0002-5795-0061
Troels YndigegnDepartment of Cardiology, Clinical Sciences, Lund University, Skane University Hospital, Lund 222 42, Sweden.ORCID 0000-0002-8960-2125
Tomas JernbergDepartment of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm 171 77, Sweden.
Claes HeldDepartment of Medical Sciences, Cardiology, Uppsala University, Uppsala 751 85, Sweden.ORCID 0000-0001-9402-7404
Erik M G OlssonDepartment of Women's and Children's Health, Uppsala University, Uppsala 751 85, Sweden.
Robin HofmannDepartment of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm, Sjukhusbacken 10, 188 83, Sweden.ORCID 0000-0002-8907-895X

Funding

Swedish Heart and Lung Association 2018:32Swedish Heart Lung Foundation 2018:32Swedish Research Council 2009-1093
6 · The paper itself

Abstract

aimsIn the Randomized Evaluation of Decreased Usage of Beta-Blockers after Acute Myocardial Infarction (REDUCE-AMI) study, long-term beta-blocker use in patients after acute myocardial infarction (AMI) with preserved left ventricular ejection fraction demonstrated no effect on death or cardiovascular outcomes. The aim of this prespecified substudy was to investigate effects of beta-blockers on self-reported quality of life and well-being. METHODS AND

resultsFrom this parallel-group, open-label, registry-based randomized clinical trial, EQ-5D, and World Health Organization well-being index-5 (WHO-5) questionnaires were obtained at 6-10 weeks and 11-13 months after AMI in 4080 and 806 patients, respectively. We report results from intention-to-treat and on-treatment analyses for the overall population and relevant subgroups using Wilcoxon rank sum test and adjusted ordinal regression analyses. Of the 4080 individuals reporting EQ-5D (median age 64 years, 22% female), 2023 were randomized to beta-blockers. The main outcome, median EQ-5D index score, was 0.94 [interquartile range (IQR) 0.88, 0.97] in the beta-blocker group, and 0.94 (IQR 0.88, 0.97) in the no-beta-blocker group 6-10 weeks after AMI, OR 1.00 [95% CI 0.89-1.13; P > 0.9]. After 11-13 months, results remained unchanged. Findings were robust in on-treatment analyses and across relevant subgroups. Secondary outcomes, EQ-VAS and WHO-5 index score, confirmed these results.

conclusionAmong patients after AMI with preserved left ventricular ejection fraction, self-reported quality of life and well-being was not significantly different in individuals randomized to routine long-term beta-blocker therapy as compared to individuals with no beta-blocker use. These results appear consistent regardless of adherence to randomized treatment and across subgroups which emphasizes the need for a careful individual risk-benefit evaluation prior to initiation of beta-blocker treatment.

Indexed as

Adrenergic beta-AntagonistsMyocardial InfarctionQuality of LifeVentricular Function, LeftAgedFemaleHumansMaleMiddle AgedRegistriesStroke VolumeTime FactorsTreatment OutcomeAdrenergic beta-AntagonistsAMI: Acute myocardial infarctionEQ-5D: EuroQoL 5-dimensionEQ-VAS: EuroQoL visual analogue scaleLVEF: Left ventricular ejection fractionQoL: Quality of lifeSWEDEHEART: Swedish Web System for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended TherapiesWHO-5: World Health Organization-5

Identifiers

PMID39217445
PMCPMC11724137

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.